Commentary on Barré et al. (2020): Identifying remaining barriers to hepatitis C treatment in the DAA era.

A response is provided to the article "Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study)" by T. Barré and others which appears in the same issue of the journal, and it mentions a low rate of treatment uptake among PWID. Direct-acting anti-viral (DAA) therapies and hepatitis C virus (HCV) treatment are addressed, along with data from places such as the United States, Australia, and Canada.